A detailed history of Kennedy Capital Management, Inc. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 4,682 shares of ITCI stock, worth $398,485. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,682
Previous 3,574 31.0%
Holding current value
$398,485
Previous $244,000 40.16%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$67.99 - $80.84 $75,332 - $89,570
1,108 Added 31.0%
4,682 $342,000
Q2 2024

Aug 14, 2024

SELL
$64.76 - $79.84 $1.02 Million - $1.26 Million
-15,747 Reduced 81.5%
3,574 $244,000
Q1 2024

May 15, 2024

SELL
$64.37 - $75.65 $517,921 - $608,679
-8,046 Reduced 29.4%
19,321 $1.34 Million
Q4 2023

Feb 14, 2024

SELL
$46.37 - $73.65 $113,606 - $180,442
-2,450 Reduced 8.22%
27,367 $1.96 Million
Q3 2023

Nov 14, 2023

SELL
$52.09 - $64.1 $2.08 Million - $2.56 Million
-39,917 Reduced 57.24%
29,817 $1.55 Million
Q2 2023

Aug 14, 2023

SELL
$54.67 - $66.44 $2.11 Million - $2.57 Million
-38,620 Reduced 35.64%
69,734 $4.42 Million
Q1 2023

May 15, 2023

SELL
$43.8 - $56.99 $8.77 Million - $11.4 Million
-200,292 Reduced 64.89%
108,354 $5.87 Million
Q4 2022

Feb 14, 2023

SELL
$44.07 - $54.45 $659,419 - $814,735
-14,963 Reduced 4.62%
308,646 $16.3 Million
Q3 2022

Nov 14, 2022

BUY
$42.7 - $59.99 $3 Million - $4.22 Million
70,290 Added 27.75%
323,609 $15.1 Million
Q2 2022

Aug 10, 2022

BUY
$43.0 - $65.64 $518,752 - $791,880
12,064 Added 5.0%
253,319 $14.5 Million
Q1 2022

May 16, 2022

BUY
$38.74 - $62.09 $1.41 Million - $2.26 Million
36,433 Added 17.79%
241,255 $14.8 Million
Q4 2021

Feb 14, 2022

BUY
$35.2 - $53.42 $3.75 Million - $5.69 Million
106,466 Added 108.25%
204,822 $10.7 Million
Q3 2021

Nov 15, 2021

BUY
$28.72 - $42.49 $2.82 Million - $4.18 Million
98,356 New
98,356 $3.67 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.03B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Kennedy Capital Management, Inc. Portfolio

Follow Kennedy Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Kennedy Capital Management, Inc. with notifications on news.